In the past week, AKYA stock has gone down by -7.59%, with a monthly decline of -31.46% and a quarterly plunge of -14.11%. The volatility ratio for the week is 6.37%, and the volatility levels for the last 30 days are 6.54% for Akoya Biosciences Inc The simple moving average for the past 20 days is -20.55% for AKYA’s stock, with a -19.93% simple moving average for the past 200 days.
Is It Worth Investing in Akoya Biosciences Inc (NASDAQ: AKYA) Right Now?
The 36-month beta value for AKYA is at 1.21. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for AKYA is 20.62M, and currently, shorts hold a 9.82% of that float. The average trading volume for AKYA on February 20, 2025 was 682.16K shares.
AKYA) stock’s latest price update
The stock price of Akoya Biosciences Inc (NASDAQ: AKYA) has plunged by -5.91 when compared to previous closing price of 2.20, but the company has seen a -7.59% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-02-18 that RINCON, Puerto Rico–(BUSINESS WIRE)–Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today highlighted its opposition to the Company’s proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake has also issued an open letter to all Quanterix shareholders outlining how the Merger significantly undervalues the Company and its intention to take all necessary step.
Analysts’ Opinion of AKYA
Many brokerage firms have already submitted their reports for AKYA stocks, with Craig Hallum repeating the rating for AKYA by listing it as a “Hold.” The predicted price for AKYA in the upcoming period, according to Craig Hallum is $5 based on the research report published on November 15, 2024 of the previous year 2024.
AKYA Trading at -19.48% from the 50-Day Moving Average
After a stumble in the market that brought AKYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.19% of loss for the given period.
Volatility was left at 6.54%, however, over the last 30 days, the volatility rate increased by 6.37%, as shares sank -35.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.72% upper at present.
During the last 5 trading sessions, AKYA fell by -6.92%, which changed the moving average for the period of 200-days by -47.74% in comparison to the 20-day moving average, which settled at $2.61. In addition, Akoya Biosciences Inc saw -9.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKYA starting from McKelligon Brian, who sale 7,500 shares at the price of $2.08 back on Jun 11 ’24. After this action, McKelligon Brian now owns 224,733 shares of Akoya Biosciences Inc, valued at $15,630 using the latest closing price.
McKelligon Brian, the President and CEO of Akoya Biosciences Inc, sale 7,500 shares at $2.01 during a trade that took place back on Jun 06 ’24, which means that McKelligon Brian is holding 224,733 shares at $15,064 based on the most recent closing price.
Stock Fundamentals for AKYA
Current profitability levels for the company are sitting at:
- -0.52 for the present operating margin
- 0.56 for the gross margin
The net margin for Akoya Biosciences Inc stands at -0.67. The total capital return value is set at -0.44. Equity return is now at value -153.34, with -37.74 for asset returns.
Based on Akoya Biosciences Inc (AKYA), the company’s capital structure generated 0.86 points at debt to capital in total, while cash flow to debt ratio is standing at -0.55. The debt to equity ratio resting at 6.23. The interest coverage ratio of the stock is -4.47.
Currently, EBITDA for the company is -45.63 million with net debt to EBITDA at -1.82. When we switch over and look at the enterprise to sales, we see a ratio of 2.02. The receivables turnover for the company is 6.79for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.75.
Conclusion
In conclusion, Akoya Biosciences Inc (AKYA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
